Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    keynote 799
Previous Study | Return to List | Next Study

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799). (KEYNOTE-799)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03631784
Recruitment Status : Recruiting
First Posted : August 15, 2018
Last Update Posted : June 20, 2019
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Tracking Information
First Submitted Date  ICMJE August 13, 2018
First Posted Date  ICMJE August 15, 2018
Last Update Posted Date June 20, 2019
Actual Study Start Date  ICMJE October 19, 2018
Estimated Primary Completion Date December 15, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 13, 2018)
  • Percentage of Participants Who Develop Grade 3 or Higher Pneumonitis [ Time Frame: Up to approximately 1 year ]
    Pneumonitis is an immune-mediated adverse event which is of interest in light of the mechanism of action of pembrolizumab.
  • Percentage of Participants with a Complete or Partial Response [ Time Frame: Up to approximately 1 year ]
    Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03631784 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 24, 2018)
  • Progression Free Survival (PFS) [ Time Frame: Up to approximately 1 year ]
    PFS defined as the time from enrollment to the first documented disease progression of local recurrence or distant metastasis or death due to any cause, whichever occurs first, as assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
  • Overall Survival (OS) [ Time Frame: Up to approximately 1 year ]
    OS is defined as the time from enrollment to death due to any cause.
  • Adverse Events (AEs) [ Time Frame: Up to approximately 1 1/4 years ]
    Percentage of participants who experienced one or more AEs.
  • Discontinuations due to AEs [ Time Frame: Up to approximately 1 year ]
    Percentage of participants discontinuing study treatment(s) due to an AE.
Original Secondary Outcome Measures  ICMJE
 (submitted: August 13, 2018)
  • Progression Free Survival (PFS) [ Time Frame: Up to approximately 1 year ]
    PFS defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
  • Overall Survival (OS) [ Time Frame: Up to approximately 1 year ]
    OS is defined as the time from enrollment to death due to any cause.
  • Adverse Events (AEs) [ Time Frame: Up to approximately 1 1/4 years ]
    Percentage of participants who experienced one or more AEs.
  • Discontinuations due to AEs [ Time Frame: Up to approximately 1 year ]
    Percentage of participants discontinuing study treatment(s) due to an AE.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799).
Official Title  ICMJE A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).
Brief Summary This is a trial in adult participants with unresectable, locally advanced, Stage III non-small cell lung cancer (NSCLC) treated with pembrolizumab in combination with platinum doublet chemotherapy and standard thoracic radiotherapy followed by pembrolizumab monotherapy. The primary hypothesis of the trial is that within each platinum doublet chemotherapy cohort, the percentage of participants who develop Grade 3 or higher pneumonitis is ≤10%.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Non-small Cell Lung Cancer
Intervention  ICMJE
  • Drug: Pembrolizumab 200 mg
    Pembrolizumab 200 mg intravenous (IV) infusion on Days 1 of each 3-week cycle for up to 17 cycles
    Other Name: MK-3475
  • Drug: Paclitaxel 45 mg/m^2
    Paclitaxel 45 mg/m^2 IV infusion on Days 1, 8, 15 of each 3-week cycle for Cycles 2, and 3 during radiation therapy.
  • Drug: Carboplatin AUC6
    Carboplatin AUC6 IV infusion on Day 1 of the 21-day cycle for Cycle 1.
  • Drug: Cisplatin 75 mg/m^2
    Cisplatin 75 mg/m^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, 3.
  • Drug: Pemetrexed 500 mg/m^2
    Pemetrexed 500 mg/m^2 IV infusion on Day 1 of each 21-day cycle for Cycles 1, 2, and 3.
  • Radiation: Thoracic Radiation Therapy (TRT)
    The target total dose of TRT will be 60 Gy in 30 daily fractions of 2 Gy, prescribed to the planning target volume.
  • Drug: Paclitaxel 200 mg/m^2
    Paclitaxel 200 mg/m^2 IV infusion on Day 1 of the 21-day cycle of Cycle 1.
  • Drug: Carboplatin AUC2
    Carboplatin AUC2 IV infusion on Day 1, 8, 15 for Cycles 2 and 3 during radiation therapy.
Study Arms  ICMJE
  • Experimental: Cohort A
    Participants will receive 1 cycle of pembrolizumab 200 mg on Day 1 with paclitaxel 200 mg/m^2, and carboplatin area under the curve (AUC) AUC6. Approximately 3 weeks later, participants will receive 2 cycles of pembrolizumab 200 mg administered every 3 weeks (Q3W) and carboplatin AUC2 with paclitaxel 45 mg/m^2 administered weekly for 6 weeks in conjunction with standard thoracic radiotherapy (60 Gray [Gy]). To conclude the study treatments, participants will receive 14 additional cycles of pembrolizumab 200 mg administered Q3W.
    Interventions:
    • Drug: Pembrolizumab 200 mg
    • Drug: Paclitaxel 45 mg/m^2
    • Drug: Carboplatin AUC6
    • Radiation: Thoracic Radiation Therapy (TRT)
    • Drug: Paclitaxel 200 mg/m^2
    • Drug: Carboplatin AUC2
  • Experimental: Cohort B
    Participants will receive 3 cycles of pembrolizumab 200 mg on Day 1 of each 3-week cycle and 3 cycles of pemetrexed 500 mg/m^2 and cisplatin 75 mg/m^2. Treatment will be given in conjunction with standard thoracic radiotherapy (60 Gy) in Cycles 2 and 3. To conclude the study treatments, participants will receive 14 additional cycles of pembrolizumab 200 mg administered Q3W.
    Interventions:
    • Drug: Pembrolizumab 200 mg
    • Drug: Cisplatin 75 mg/m^2
    • Drug: Pemetrexed 500 mg/m^2
    • Radiation: Thoracic Radiation Therapy (TRT)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: August 13, 2018)
216
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 14, 2022
Estimated Primary Completion Date December 15, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male/female participants, who are at least 18 years of age on the day of signing informed consent with previously untreated, unresectable, pathologically confirmed NSCLC and Stage IIIA, IIIB or IIIC NSCLC by American Joint Committee on Cancer Version 8.
  • No evidence of metastatic disease by whole body positron emission tomography/computed tomography (PET/ CT) scan, diagnostic quality CT scan, and brain imaging.
  • Have measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.
  • Have provided tumor tissue sample (core, incisional, or excisional biopsy).
  • Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Have adequate pulmonary function test (PFT)
  • Have adequate organ function
  • A male participant must agree to use contraception through the end of treatment and refrain from donating sperm during this period.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and if participant is a woman of childbearing potential (WOCBP), agrees to follow the contraceptive guidance as provided in the protocol through the end of treatment.

Exclusion Criteria:

  • A WOCBP who has a positive urine pregnancy test within 72 hours prior to treatment allocation
  • Has small cell lung cancer.
  • Has had documented weight loss >10% in the preceding 3 months.
  • Participants whose radiation treatment plans are likely to encompass a volume of whole lung receiving >20 Gy in total (V20) of more than 31% of lung volume.
  • Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus or for breast cancer.
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (programmed cell death protein 1 [PD-1] and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 [PD-L2]) or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
  • Has received a live vaccine within 30 days prior to the first dose of study drug.
  • Has had an allogenic tissue/solid organ transplant.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.
  • Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.
  • Has severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or any of its excipients.
  • Has a known severe hypersensitivity (Grade 3 or higher) to any of the study chemotherapy agents and/or to any of their excipients.
  • Has an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
  • Has a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease that requires steroids.
  • Has an active infection requiring systemic therapy.
  • Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
  • Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
  • Has a known history of active tuberculosis (TB; Bacillus tuberculosis).
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Has a known psychiatric or substance abuse disorder that would interfere with cooperating with the requirements of the study.
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study through the end of treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com
Listed Location Countries  ICMJE Australia,   France,   Germany,   Korea, Republic of,   New Zealand,   Poland,   Russian Federation,   Spain,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03631784
Other Study ID Numbers  ICMJE 3475-799
MK-3475-799 ( Other Identifier: Merck Protocol Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php
Responsible Party Merck Sharp & Dohme Corp.
Study Sponsor  ICMJE Merck Sharp & Dohme Corp.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Medical Director Merck Sharp & Dohme Corp.
PRS Account Merck Sharp & Dohme Corp.
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP